Pulmonary outcome prediction for cystic fibrosis patients

Kraemer, Richard; Thamrin, Cindy

doi:10.1002/ppul.21320

Cited by 5 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spirometry is the most frequently applied test of respiratory function. However, it has wellrecognized limitations with respect to the above considerations in general, and certainly for CF (49)(50)(51)(52)(53)(54)(55)102,(158)(159)(160)(161) The reasons for this are not fully understood and may simply represent unrealistic expectations. However, there are a number of factors that likely do contribute in this regard (159).…”

Section: Rationalementioning

confidence: 99%

“…To adjust for multiple comparisons, the False Discovery Rate (FDR) proposed by Benjamini and Hochberg was utilized.Evaluating lung function in CF is a fundamental aspect of patient care, and spirometry remains the pulmonary function test most commonly used for this purpose. While extremely useful, there are well-recognized limitations as noted earlier(49)(50)(51)(52)(53)(54)(55)102,158,160,161). Oscillometry has been utilized in research for many years and is now being used more frequently in clinical settings such as asthma and COPD.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Oscillometry to Assess Respiratory Function in Adult Cystic Fibrosis

Rad

Landry

Dong

et al. 2020

B30. Arthur Dubois Memorial Session: The Small and Large of Airway and Lung Function

View full text Add to dashboard Cite

Oscillometry to Assess Respiratory Function in Adult Cystic FibrosisBackground and Rationale: Cystic fibrosis (CF) is a life-limiting multi-system disorder in which respiratory dysfunction predominates. Although spirometry is the most commonly used test of pulmonary function, it has recognized limitations. Oscillometry is an alternative test of respiratory function which provides complementary information. Oscillometry also offers a number of practical and physiological advantages and is increasingly used in both clinical research and patient care. Surprisingly, little data exists using oscillometry to evaluate lung function in adults with CF.Accordingly, the aim of this study was to compare spirometry and oscillometry in a large adult CF cohort. Methods: Spirometry and oscillometry (tremoFlo® C-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada) were performed according to published guidelines during a routine visit to the Montreal Chest Institute Adult CF Clinic, McGill University Health Centre in 92 adults with established CF in stable state (mean age = 33.0 ± SE 1.3 yrs, 51 men). Oscillometry parameters included respiratory resistance at 5 Hz (R5), the difference in respiratory resistance at 5 and 20 Hz (R5-20), respiratory reactance at 5 Hz (X5), respiratory reactance area (AX), and resonant frequency (Fres).Results: Respiratory function was significantly reduced for the group (forced expiratory volume in one second, FEV1 = 2.27 ± SE 0.1 L; Z score = -3.38 ± SE 0.23). There was generally a good to strong correlation between spirometry and oscillometry parameters, particularly between FEV1 and both X5 and AX, and all relationships were highly significant (P < 0.001). Results were generally similar when expressed as absolute values or Z scores. Logistic regression and marginal

show abstract

Section: Rationalementioning

confidence: 99%

mentioning

confidence: 99%

Oscillometry to Assess Respiratory Function in Adult Cystic Fibrosis

Rad

Landry

Dong

et al. 2020

B30. Arthur Dubois Memorial Session: The Small and Large of Airway and Lung Function

View full text Add to dashboard Cite

show abstract

“…Pulmonary function expressed as forced expiratory volume in 1 s (FEV 1 ) and that fraction of an individual’s FEV 1 retained compared with a healthy reference population of similar height, age and sex (FEV 1 % predicted) are highly (some would say disproportionately [15,16]) prominent measures in CF clinical care and research. As noted, more than four out of five CF deaths today are the direct or indirect result of loss of pulmonary function [2,3].…”

Section: Improvement/stabilization Of Pulmonary Functionmentioning

confidence: 99%

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease

VanDevanter¹,

Konstan²

2012

Clinical Investigation

View full text Add to dashboard Cite

Cystic fibrosis (CF) is a complex genetic disease characterized by death from loss of lung function. Therapies target pathophysiologic changes associated with pulmonary disease progression. Although therapeutic mechanisms differ, efficacy demonstration is limited to a few accepted outcome measures, each with shortcomings that are becoming more pronounced as CF population health improves. Pulmonary function improvement (as forced expiratory volume in 1 s [FEV1]) and reduction of pulmonary exacerbation risk are commonly used outcomes. Changes in FEV1 decline rate, quality of life, linear growth and/or weight gain are less utilized outcomes. Validated outcomes tend to work best in subjects with more aggressive or advanced lung disease and less so in healthier subjects. Assays of effects on primary therapeutic targets have yet to be validated as surrogate measures of clinical efficacy. As CF population health improves, it will become increasingly difficult to employ current clinical outcome measures to demonstrate efficacy.

show abstract

L’indice de clairance pulmonaire dans la mucoviscidose

Poncin

Lebecque

2019

Revue des Maladies Respiratoires

View full text Add to dashboard Cite

Pulmonary outcome prediction for cystic fibrosis patients

Cited by 5 publications

References 24 publications

Oscillometry to Assess Respiratory Function in Adult Cystic Fibrosis

Oscillometry to Assess Respiratory Function in Adult Cystic Fibrosis

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease

L’indice de clairance pulmonaire dans la mucoviscidose

Contact Info

Product

Resources

About